You are here: Industry Insights > TrippBio

News List

TrippBio receives Notice of Allowance from the U.S. Patent Office for Therapeutic Treatment of COVID-19 Infections firstwordpharma
July 16, 2021
TrippBio, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/875,487, and the European Patent Office (EPO) has issued a favorable opinion in a counterpart European application.
TrippBio Reports Positive Results from Investigator-Initiated Clinical Trial of TD213 for the Treatment of Mild to Moderate COVID-19 Infections prnewswire
November 17, 2020
TrippBio is dedicated to developing groundbreaking treatments for viral infections, initially targeting COVID-19. TrippBio is developing a patent-pending repurposed FDA-approved drug called TD213.
TrippBio Completes Trial Enrollment to Evaluate Efficacy of TD213 for COVID-19 americanpharmaceuticalreview
October 29, 2020
TrippBio is developing a patent-pending repurposed FDA-approved drug, TD213. TD213 works by blocking the SARS-CoV-2 virus' replication and the associated acute inflammatory response to the infection.
TrippBio Announces the Completion of Enrollment in a Proof of Concept Clinical Trial Evaluating the Efficacy of TD213 in Treating Patients with Confirmed COVID-19 Infections prnewswire
October 23, 2020
TrippBio is a biotechnology company dedicated to developing groundbreaking treatments for viral infections initially targeting the global pandemic caused by COVID-19.